{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"U3-1402a"},{"type":"CodeName","name":"U3 1402"},{"type":"Synonym","name":"anti-HER3 antibody-drug conjugate U3 1402"},{"type":"CodeName","name":"U3-1402"},{"type":"CASRegistryName","name":"2227102-46-5"}],"definition":{"html":"An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),linked to the topoisomerase I inhibitor DX 8951, a semisynthetic, water-soluble derivative of camptothecin, with potential antineoplastic activity. Upon administration of patritumab deruxtecan, the patritumab moiety targets and binds to HER3. After internalization, DX 8951 inhibits topoisomerase I activity by stabilizing the complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors.","text":"An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),linked to the topoisomerase I inhibitor DX 8951, a semisynthetic, water-soluble derivative of camptothecin, with potential antineoplastic activity. Upon administration of patritumab deruxtecan, the patritumab moiety targets and binds to HER3. After internalization, DX 8951 inhibits topoisomerase I activity by stabilizing the complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors."},"drugInfoSummaryLink":null,"nciConceptId":"C136987","nciConceptName":"Patritumab Deruxtecan","termId":789807,"name":"patritumab deruxtecan","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"patritumab-deruxtecan"}],"links":null}